ArticleMicrosystems & nanoengineering2025
Fluidic-manipulation-enabled multiplexed dose delivery of RONS by a CAP chip for dose optimization enhancement.
Article in Microsystems & nanoengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The plasma-derived reactive oxygen and nitrogen species (RONS) enable cold atmospheric plasma (CAP) to combat cancer and infectious wounds. Achieving therapeutic outcomes with CAP necessitates precise treatment doses. Current CAP devices are constrained by their capability of delivering a single dose to a single sample, limiting dose optimization. We propose a novel "one exposure, multiple-dose delivery" strategy by programming gas flows. This approach facilitates efficient screening of optimal CAP dose by distributing feed gas through boundary-conditioned transport channels to generate multiple, flux-varied gas streams, which ignite plasmas with diverse chemical compositions and dose gradients across samples. Our developed demonstration device, capable of administering three doses to sixteen samples, significantly reduces experimental complexity, particularly when handling large candidate doses or samples for treatment. Leveraging multiplexed treatment, we capably optimize the CAP dose to effectively eradicate the liver cancer cell line of Huh7 and bacteria of S. aureus within one exposure. Furthermore, we find manipulating gas flow velocities allows targeted generation of short-lived species. This approach disentangles the roles of short-lived and long-lived RONS in therapeutic applications, offering critical insights into their bio-functional mechanisms. The concept of multiplexed dose treatment with fluidic manipulation promises to catalyze the development of high-efficiency CAP devices and advance research in CAP-based therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.